Literature DB >> 10959413

Mammary gland development and the prolactin receptor.

N Binart1, C J Ormandy, P A Kelly.   

Abstract

Prolactin (PRL), synthesized by the anterior pituitary and to a lesser extent by numerous extrapituitary tissues, affects more physiological processes than all other pituitary hormones combined. This hormone is involved in > 300 separate effects in various vertebrate species where its role has been well documented. The initial step in its action is the binding to a specific membrane receptor which belongs to the superfamily of class 1 cytokine receptors. The function of this receptor is mediated, at least in part, by two families of signaling molecules: Janus kinases and signal transducers and activators of transcription. PRL-binding sites have been identified in a number of cells and tissues of adult animals. Disruption of the gene for the PRL receptor has provided a new animal model with which to better understand the actions of PRL on mammary morphogenesis and mammary gland gene expression. The recent availability of genetic mouse models provides new insights into mammary developmental biology and how the action of a hormone at specific stages of development can have effects later in life on processes such as mammary development and breast cancer initiation and progression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10959413     DOI: 10.1007/0-306-46832-8_10

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  8 in total

1.  A pathway map of prolactin signaling.

Authors:  Aneesha Radhakrishnan; Rajesh Raju; Nirvana Tuladhar; Tejaswini Subbannayya; Joji Kurian Thomas; Renu Goel; Deepthi Telikicherla; Shyam Mohan Palapetta; B Abdul Rahiman; Desai Dattatraya Venkatesh; Kulkarni-Kale Urmila; H C Harsha; Premendu Prakash Mathur; T S Keshava Prasad; Akhilesh Pandey; Carrie Shemanko; Aditi Chatterjee
Journal:  J Cell Commun Signal       Date:  2012-06-09       Impact factor: 5.782

2.  Prolactin-stimulated activation of ERK1/2 mitogen-activated protein kinases is controlled by PI3-kinase/Rac/PAK signaling pathway in breast cancer cells.

Authors:  Edita Aksamitiene; Sirisha Achanta; Walter Kolch; Boris N Kholodenko; Jan B Hoek; Anatoly Kiyatkin
Journal:  Cell Signal       Date:  2011-06-25       Impact factor: 4.315

3.  Image-based evaluation of the molecular events underlying HC11 mammary epithelial cell differentiation.

Authors:  Liang Shan; Renshu Zhang; Wanghai Zhang; Edward Lee; Rajagopalan Sridhar; Elizabeth G Snyderwine; Paul C Wang
Journal:  Anal Biochem       Date:  2008-08-08       Impact factor: 3.365

4.  Prolactin receptor expression and breast cancer: relationships with tumor characteristics among pre- and post-menopausal women in a population-based case-control study from Poland.

Authors:  Jessica M Faupel-Badger; Maire A Duggan; Mark E Sherman; Montserrat Garcia-Closas; Xiaohong R Yang; Jolanta Lissowska; Louise A Brinton; Beata Peplonska; Barbara K Vonderhaar; Jonine D Figueroa
Journal:  Horm Cancer       Date:  2013-11-19       Impact factor: 3.869

5.  Establishing a relationship between prolactin and altered fatty acid β-oxidation via carnitine palmitoyl transferase 1 in breast cancer cells.

Authors:  Katja Linher-Melville; Stephanie Zantinge; Toran Sanli; Hertzel Gerstein; Theodoros Tsakiridis; Gurmit Singh
Journal:  BMC Cancer       Date:  2011-02-04       Impact factor: 4.430

6.  Mouse models of estrogen receptor-positive breast cancer.

Authors:  Shakur Mohibi; Sameer Mirza; Hamid Band; Vimla Band
Journal:  J Carcinog       Date:  2011-12-22

7.  Progesterone receptor isoform-dependent cross-talk between prolactin and fatty acid synthase in breast cancer.

Authors:  Javier A Menendez; Susan K Peirce; Adriana Papadimitropoulou; Elisabet Cuyàs; Travis Vander Steen; Sara Verdura; Luciano Vellon; Wen Y Chen; Ruth Lupu
Journal:  Aging (Albany NY)       Date:  2020-12-10       Impact factor: 5.682

8.  Prolactin acts as a potent survival factor for human breast cancer cell lines.

Authors:  C M Perks; A J Keith; K L Goodhew; P B Savage; Z E Winters; J M P Holly
Journal:  Br J Cancer       Date:  2004-07-19       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.